Andreas Argyrides
Stock Analyst at Oppenheimer
(4.54)
# 253
Out of 5,124 analysts
118
Total ratings
54.9%
Success rate
22.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $19.56 | +104.50% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $6.03 | +49.25% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $20.36 | +32.61% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $65.30 | +76.11% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.81 | +451.18% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $13.47 | +115.29% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.56 | +5,836.32% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $487.25 | +18.01% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.67 | +164.55% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $5.27 | +279.51% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $37.42 | +63.01% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $6.46 | +8.36% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.01 | +197.03% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $34.49 | -62.31% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.35 | +196.30% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $8.01 | +1,023.60% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.02 | +345.54% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $213.24 | -15.12% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $13.18 | +689.07% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $3.10 | +190.32% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $11.65 | +63.09% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.97 | +45.22% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $14.41 | +45.73% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $21.52 | +940.89% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.88 | +120.25% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.53 | +1,211.60% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.42 | +2,280.95% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $59.43 | +17.79% | 6 | Aug 1, 2023 |
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $19.56
Upside: +104.50%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $6.03
Upside: +49.25%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $20.36
Upside: +32.61%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $65.30
Upside: +76.11%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.81
Upside: +451.18%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $13.47
Upside: +115.29%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.56
Upside: +5,836.32%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $487.25
Upside: +18.01%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.67
Upside: +164.55%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.27
Upside: +279.51%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $37.42
Upside: +63.01%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $6.46
Upside: +8.36%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.01
Upside: +197.03%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $34.49
Upside: -62.31%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.35
Upside: +196.30%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $8.01
Upside: +1,023.60%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.02
Upside: +345.54%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $213.24
Upside: -15.12%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $13.18
Upside: +689.07%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $3.10
Upside: +190.32%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $11.65
Upside: +63.09%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.97
Upside: +45.22%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $14.41
Upside: +45.73%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $21.52
Upside: +940.89%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.88
Upside: +120.25%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.53
Upside: +1,211.60%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.42
Upside: +2,280.95%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $59.43
Upside: +17.79%